HUP0103781A3 - Pharmaceutical compositions comprising atypical antiphsychotic agent in combination with acetylcholinesterase inhibitor for improving cognition - Google Patents

Pharmaceutical compositions comprising atypical antiphsychotic agent in combination with acetylcholinesterase inhibitor for improving cognition

Info

Publication number
HUP0103781A3
HUP0103781A3 HU0103781A HUP0103781A HUP0103781A3 HU P0103781 A3 HUP0103781 A3 HU P0103781A3 HU 0103781 A HU0103781 A HU 0103781A HU P0103781 A HUP0103781 A HU P0103781A HU P0103781 A3 HUP0103781 A3 HU P0103781A3
Authority
HU
Hungary
Prior art keywords
antiphsychotic
atypical
agent
combination
pharmaceutical compositions
Prior art date
Application number
HU0103781A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of HUP0103781A2 publication Critical patent/HUP0103781A2/hu
Publication of HUP0103781A3 publication Critical patent/HUP0103781A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
HU0103781A 1998-10-16 1999-10-12 Pharmaceutical compositions comprising atypical antiphsychotic agent in combination with acetylcholinesterase inhibitor for improving cognition HUP0103781A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98203454 1998-10-16
PCT/EP1999/007804 WO2000023057A2 (en) 1998-10-16 1999-10-12 Atypical antiphsychotic in combination with acetylcholinesterase inhibitor for improving cognition

Publications (2)

Publication Number Publication Date
HUP0103781A2 HUP0103781A2 (hu) 2002-03-28
HUP0103781A3 true HUP0103781A3 (en) 2003-09-29

Family

ID=8234219

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0103781A HUP0103781A3 (en) 1998-10-16 1999-10-12 Pharmaceutical compositions comprising atypical antiphsychotic agent in combination with acetylcholinesterase inhibitor for improving cognition

Country Status (20)

Country Link
EP (1) EP1121131A2 (de)
JP (1) JP2002527469A (de)
KR (1) KR20010072878A (de)
CN (1) CN1367697A (de)
AU (1) AU6472799A (de)
BG (1) BG105302A (de)
BR (1) BR9914419A (de)
CA (1) CA2345767A1 (de)
EE (1) EE200100136A (de)
HK (1) HK1039745A1 (de)
HR (1) HRP20010262A2 (de)
HU (1) HUP0103781A3 (de)
ID (1) ID28441A (de)
IL (1) IL142588A0 (de)
NO (1) NO20011403L (de)
PL (1) PL348107A1 (de)
SK (1) SK4592001A3 (de)
TR (1) TR200101082T2 (de)
WO (1) WO2000023057A2 (de)
ZA (1) ZA200103081B (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0102841D0 (en) * 2001-02-05 2001-03-21 Novartis Ag Organic compounds
AU2006201188B2 (en) * 2001-02-05 2007-11-15 Novartis Ag New use of iloperidone
BRPI0213564B8 (pt) 2001-10-30 2021-05-25 Novartis Ag formulação depósito e micropartícula compreendendo iloperidona e polímero poli(d,l-lactídeo-co-glicolídeo), e processo para preparação da referida micropartícula
GB0216416D0 (en) 2002-07-15 2002-08-21 Novartis Ag Organic compounds
US20040192754A1 (en) * 2003-03-24 2004-09-30 Shapira Nathan Andrew Methods for treating idiopathic hyperhidrosis and associated conditions
TW200501962A (en) * 2003-04-01 2005-01-16 Novartis Ag Use of carbamazepine derivatives for the treatment of agitation in dementia patients
WO2006065233A1 (en) * 2004-12-10 2006-06-22 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
WO2005065645A2 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Donepezil formulations
US8278345B2 (en) 2006-11-09 2012-10-02 Probiodrug Ag Inhibitors of glutaminyl cyclase
ATE554085T1 (de) 2006-11-30 2012-05-15 Probiodrug Ag Neue inhibitoren von glutaminylcyclase
JP5930573B2 (ja) 2007-03-01 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤の新規使用
EP2142514B1 (de) 2007-04-18 2014-12-24 Probiodrug AG Thioharnstoffderivate als glutaminylcyclaseinhibitoren
MX2007008642A (es) * 2007-07-16 2009-02-25 World Trade Imp Export Wtie Ag Composicion farmaceutica que comprende la combinacion de un agente derivado benzisoxazolico y un agente inhibidor reversible de la enzima colinesterasa, indicada para el control y tratamiento de trastornos psicoticos y demencias.
AU2011215870B2 (en) 2010-02-09 2016-01-28 The Johns Hopkins University Methods and compositions for improving cognitive function
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
NZ602312A (en) 2010-03-10 2014-02-28 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
EP2686313B1 (de) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazolderivate als glutaminylcyclase-hemmer
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
JP6433482B2 (ja) 2013-03-15 2018-12-05 エージンバイオ， インコーポレイテッド 認知機能を改善するための方法および組成物
WO2016191288A1 (en) 2015-05-22 2016-12-01 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5336675A (en) * 1991-05-14 1994-08-09 Ernir Snorrason Method of treating mania in humans
WO1992020327A1 (en) * 1991-05-14 1992-11-26 Ernir Snorrason Treatment of fatigue syndrome with cholinesterase inhibitors
JP4640888B2 (ja) * 1997-08-11 2011-03-02 ザ ユニヴァーシティー オブ サウス フロリダ 神経精神性疾患用ニコチンアンタゴニスト
EP1073432B1 (de) * 1998-04-14 2007-08-15 The General Hospital Corporation Verwendung von d-serine oder d-alanine zur behandlung von schizophrenie

Also Published As

Publication number Publication date
WO2000023057A3 (en) 2000-07-27
TR200101082T2 (tr) 2001-09-21
HRP20010262A2 (en) 2002-06-30
HUP0103781A2 (hu) 2002-03-28
HK1039745A1 (zh) 2002-05-10
NO20011403D0 (no) 2001-03-20
CN1367697A (zh) 2002-09-04
WO2000023057A2 (en) 2000-04-27
AU6472799A (en) 2000-05-08
CA2345767A1 (en) 2000-04-27
BR9914419A (pt) 2001-06-26
NO20011403L (no) 2001-03-20
EP1121131A2 (de) 2001-08-08
SK4592001A3 (en) 2001-12-03
BG105302A (en) 2001-11-30
KR20010072878A (ko) 2001-07-31
IL142588A0 (en) 2002-03-10
PL348107A1 (en) 2002-05-06
ID28441A (id) 2001-05-24
ZA200103081B (en) 2002-07-12
JP2002527469A (ja) 2002-08-27
EE200100136A (et) 2002-06-17

Similar Documents

Publication Publication Date Title
HUP0103781A3 (en) Pharmaceutical compositions comprising atypical antiphsychotic agent in combination with acetylcholinesterase inhibitor for improving cognition
IL206621A0 (en) Caspase inhibitors and pharmaceutical compositions containing the same
HUP0104768A3 (en) 4-amino-3-oxo-azepanes as protease inhibitors and pharmaceutical compositions containing the same
HUP0302922A3 (en) Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation and pharmaceutical compositions containing them
IL177018A0 (en) Cyclopropyl-fused pyrrolidine derivatives and pharmaceutical compositions containing the same
IL150224A0 (en) Lipopeptides and pharmaceutical compositions containing the same
IL150223A0 (en) Lipopeptides and pharmaceutical compositions containing the same
HUP0203971A3 (en) Imidazoimidazoles and triazoles as anti-inflammatory agents and pharmaceutical compositions containing them and their use
HUP0203378A3 (en) Pharmaceutical compounds and pharmaceutical compositions containing them
EP1329456A4 (de) Glucopyranosyloxybenzylbenzol derivate und medizinische zusammensetzungen, die diese verbindungen enthalten
HUP0103188A2 (hu) Vegyületek és készítmények hatóanyagok célbajuttatására
IL152315A0 (en) Soluble ctla4 mutant molecules and pharmaceutical compositions containing the same
IL152718A0 (en) Piperidine derivatives and pharmaceutical compositions containing the same
IL138899A0 (en) Amidene derivatives and pharmaceutical compositions containing the same
HUP0203965A3 (en) Indazole compounds and pharmaceutical compositions containing them
IL156558A0 (en) Novel quinuclidine derivatives and medicinal compositions containing the same
HUP0203939A3 (en) Pharmaceutical compounds and compositions containing them and their use
IL140862A (en) Thiobenzimidazole derivatives and pharmaceutical compositions containing the same
IL154981A0 (en) Substituted indoles, pharmaceutical compositions containing such indoles and their use as ppay-y-binding agents
IL149580A0 (en) Analgesic compositions containing buprenorphine
IL143920A0 (en) 3-heteroarylidenyl-2-indolinone derivatives and pharmaceutical compositions containing the same
IL152846A0 (en) Pyridazinone derivatives and pharmaceutical compositions containing the same
IL138572A0 (en) Benzoate derivatives and pharmaceutical compositions containing the same
HUP0000137A3 (en) Controller-release pharmaceutical composition containing anangetics
IL147214A0 (en) 1-methylcarbapenem derivatives and pharmaceutical compositions containing the same